Full Results Of Study Comparing Tamoxifen, Raloxifene In Reducing Breast Cancer Risk Presented At Oncology Conference
Main Category: Breast CancerArticle Date: 08 Jun 2006 - 16:00 PDT
| Patient / Public: | ![]() |
4 (4 votes) |
| Healthcare Prof: | ![]() |
5 (1 votes) |
Researchers on Monday at a meeting of the American Society of Clinical Oncology presented the full findings from a National Cancer Institute-sponsored study comparing the effectiveness of two drugs -- tamoxifen, an FDA-approved drug for reducing breast cancer risk, and raloxifene, a bone strengthening drug sold by Eli Lilly under the brandname Evista -- in reducing the risk of developing breast cancer, the New York Times reports. The study was published on the Journal of the American Medical Association Web site on Monday. The initial results of the study, which examined 19,747 postmenopausal women, found that both drugs reduced a woman's risk of developing breast cancer by about half. According to the study, raloxifene resulted in fewer cases of blood clots, cataracts and uterine cancers, though the difference between tamoxifen and raloxifene in the risk of developing blood clots and uterine cancer was not statistically significant, the Times reports. In newer results presented at the conference on Monday, researchers showed a detailed analysis of the two drugs' side effects and a survey on the physical and mental well-being of about 10% of study participants. According to the newly presented data, there was no difference between the drugs in terms of self-described physical or mental health or depression. Women who took tamoxifen were more likely to experience hot flashes, vaginal bleeding, bladder control problems and leg cramps, and women taking raloxifene were more likely to experience pain during sexual intercourse and joint pain, according to the survey. The Times reports that the new data are not likely to end the debate about whether tamoxifen or raloxifene is better in reducing breast cancer risk (Pollack, New York Times, 6/6).
"Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Visit our breast cancer section for the latest news on this subject.
MLA
12 Feb. 2012. <http://www.medicalnewstoday.com/releases/44700.php>
APA
http://www.medicalnewstoday.com/releases/44700.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.





